Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

Executive Summary

Despite returning positive results in the MONARCH-3 trial, Lilly's breast cancer therapy abemaciclib has sparked mixed reactions at ESMO; the big pharma will need to work on differentiating the drug from other CDK 4/6 therapies.


Related Content

Lilly Math: Subtracting Employees And Animal Health Equals Pharma Growth
And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts